{"article_title": "U.S., Australia reach deal on pharma protection in TPP: Japan media", "article_keywords": ["week", "sticking", "australia", "pharma", "deal", "rights", "media", "point", "reach", "transpacific", "reported", "protection", "reportreporting", "tpp", "talks", "japan", "proposal", "data"], "article_url": "http://www.thefiscaltimes.com/latestnews/2015/10/04/Australia-sees-way-resolve-TPP-drug-dispute-United-States", "article_text": "The amount of time allowed for pharmaceutical companies to have exclusive rights to the clinical data for biological drugs has been the last major sticking point in the Trans-Pacific Partnership talks in Atlanta.\n\nThe compromise under discussion would grant a data exclusivity period that would be eight years, in effect, Kyodo reported. That would be in line with a U.S. proposal from last week. Reuters could not immediately confirm the report.\n\n(Reporting by Kevin Krolicki)", "article_metadata": {"og": {"site_name": "The Fiscal Times", "description": "The amount of time allowed for pharmaceutical companies to have exclusive rights to th", "title": "U.S., Australia reach deal on pharma protection in TPP: Japan media", "url": "http://www.thefiscaltimes.com/latestnews/2015/10/04/Australia-sees-way-resolve-TPP-drug-dispute-United-States", "image": "http://cdn.thefiscaltimes.com/sites/default/files/reuters/trade-tpp_1.jpg", "type": "article"}, "twitter": {"url": "http://www.thefiscaltimes.com/latestnews/2015/10/04/Australia-sees-way-resolve-TPP-drug-dispute-United-States", "image": "http://cdn.thefiscaltimes.com/sites/default/files/reuters/trade-tpp_1.jpg", "card": "summary", "title": "The Fiscal Times"}, "viewport": "initial-scale=1, maximum-scale=1", "description": "The amount of time allowed for pharmaceutical companies to have exclusive rights to th", "generator": "Drupal 7 (http://drupal.org)"}, "article_summary": "The compromise under discussion would grant a data exclusivity period that would be eight years, in effect, Kyodo reported.\nThe amount of time allowed for pharmaceutical companies to have exclusive rights to the clinical data for biological drugs has been the last major sticking point in the Trans-Pacific Partnership talks in Atlanta.\nThat would be in line with a U.S. proposal from last week.\nReuters could not immediately confirm the report.\n(Reporting by Kevin Krolicki)"}